Are there generic versions of brigatinib/brigatinib?

Brigatinib/Brigatinib (Brigatinib) is a second-generation irreversible ALK inhibitor used to treat ALK-positive metastatic non-small cell lung cancer (NSCLC). As an original drug, it has been approved in many countries around the world. However, due to patent protection and research and development costs, the price of original drugs is higher, which makes some patients pay more attention to the feasibility and cost-effectiveness of generic drugs.

Generic drugs of brigatinib do exist in overseas markets. These generic drugs are mostly produced by some Asian pharmaceutical companies, such as Laos Lucius Pharmaceuticals, Laos Second Pharmaceutical Factory, Laos United Pharmaceuticals, Laos ASEAN Pharmaceuticals, and Yaopin International and Beacon Pharmaceuticals of Bangladesh. These generic drugs are basically the same as the original drugs in terms of pharmaceutical ingredients and follow the same dosage of active ingredients and oral administration method as the original drugs. When patients use these generic drugs, they can obtain similar targeted inhibitory effects while reducing the economic burden.

At present, there are no self-produced generic brigatinib drugs on the market in China, and patients still have to rely on imported original drugs to purchase drugs domestically. For patients who want to use more cost-effective drugs, some overseas generic drugs are available through legal imports or cross-border medical channels. However, before use, it is necessary to ensure that the source of the drugs is formal to avoid the risk of counterfeit drugs.

From a pharmacological perspective, brigatinib generic drugs block downstream signaling pathways by irreversibly bindingALK tyrosine kinase, inhibiting tumor cell proliferation and delaying disease progression. Generic drugs contain the same active ingredients as the brand-name drugs and are absorbed in the body and last for the same duration of effect, making them an economical alternative for patients. Overall, although domestic generic drugs are not yet on the market, overseas generic drugs have provided feasible treatment options for some patients, providing more medication flexibility for ALK-positive NSCLC patients around the world.

Reference materials:https://www.alunbrig.com/